We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · July 04, 2022

Rivaroxaban and Aspirin vs Aspirin Alone in Asian Compared With Non-Asian Patients With Chronic CAD or PAD

European Heart Journal

 

Additional Info

European Heart Journal
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial
Eur Heart J 2022 Jun 25;[EPub Ahead of Print], M Hori, J Zhu, Y Liang, DL Bhatt, J Bosch, SJ Connolly, KAA Fox, A Maggioni, S Yusuf, JW Eikelboom

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading